EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity

Hitomi Yagi, Myriam Boeck, Mariya Petrishka-Lozenska, Pia Lundgren, Taku Kasai, Gael Cagnone, Katherine Neilsen, Chaomei Wang, Jeff Lee, Yohei Tomita, Sasha A Singh, Jean-Sébastien Joyal und 5 weitere

Angiogenesis · 2024

DOI: 10.1007/s10456-024-09948-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angiogenesis, 2024. Verfasst von Hitomi Yagi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, 3 Blackfan Circle, CLS 18, Boston, MA, 02115, USA. Hauptthemen laut MEDLINE: Dexamethasone, Retinopathy of Prematurity, Mitochondria, Ophthalmic Solutions. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Government grants under the ALF agreement, NEI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathological neovascularization in retinopathy of prematurity (ROP) can cause visual impairment in preterm infants. Current ROP treatments which are not preventative and only address late neovascular ROP, are costly and can lead to severe complications. We showed that topical 0.1% dexamethasone eye drops administered prior to peak neovessel formation prevented neovascularization in five extremely preterm infants at high risk for ROP and suppressed neovascularization by 30% in mouse oxygen-induced retinopathy (OIR) modeling ROP. In contrast, in OIR, topical dexamethasone treatment before any neovessel formation had limited efficacy in preventing later neovascularization, while treatment after peak neovessel formation had a non-statistically significant trend to exacerbating disease. Optimally timed topical dexamethasone suppression of neovascularization in OIR was associated with increased retinal mitochondrial gene expression and decreased inflammatory marker expression, predominantly found in immune cells. Blocking mitochondrial ATP synthetase reversed the inhibitory effect of dexamethasone on neovascularization in OIR. This study provides new insights into topical steroid effects in retinal neovascularization and into mitochondrial function in phase II ROP, and suggests a simple clinical approach to prevent severe ROP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneRetinopathy of PrematurityMitochondriaOphthalmic SolutionsAnimalsHumansInfant, NewbornMiceAdministration, TopicalFemaleRetinal NeovascularizationMice, Inbred C57BLMaleDisease Models, Animal

Stichwörter der Autor:innen

DexamethasoneEye dropsMitochondrial functionNeovascularizationOxygen-induced retinopathyRetinopathy of prematurity

Substanzen

DexamethasoneOphthalmic Solutions

Autor:innen und Institutionen

  • Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, 3 Blackfan Circle, CLS 18, Boston, MA, 02115, USA.
  • Department of Ophthalmology, Keio University School of Medicine, Tokyo, 160-8582, Japan.
  • Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, 79106, Germany.
  • The Sahlgrenska Centre for Pediatric Ophthalmology Research, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 40530, Sweden.
  • Center for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Department of Medicine, Brigham Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • CHU Sainte-Justine Research Center, Montreal, QC, CA, H3T 1C5, Canada.

Förderung

  • Government grants under the ALF agreement
  • NEI NIH HHS
  • NHLBI NIH HHS
  • NICHD NIH HHS
  • Boston Children's Hospital
  • Svenska Forskningsrådet Formas
  • National Institutes of Health
  • Kowa Company

Zitieren

APA

Yagi, H., Boeck, M., Petrishka-Lozenska, M., Lundgren, P., Kasai, T., Cagnone, G., Neilsen, K., Wang, C., Lee, J., Tomita, Y., Singh, S. A., Joyal, J. S., Aikawa, M., Negishi, K., Fu, Z., Hellström, A., & Smith, L. E. H. (2024). Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity. Angiogenesis. https://doi.org/10.1007/s10456-024-09948-2

Vancouver

Yagi H, Boeck M, Petrishka-Lozenska M, Lundgren P, Kasai T, Cagnone G, et al. Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity. Angiogenesis. 2024. doi:10.1007/s10456-024-09948-2

BibTeX
@article{Yagi2024,
  author = {Yagi, Hitomi and Boeck, Myriam and Petrishka-Lozenska, Mariya and Lundgren, Pia and Kasai, Taku and Cagnone, Gael and Neilsen, Katherine and Wang, Chaomei and Lee, Jeff and Tomita, Yohei and Singh, Sasha A and Joyal, Jean-Sébastien and Aikawa, Masanori and Negishi, Kazuno and Fu, Zhongjie and Hellström, Ann and Smith, Lois E H},
  title = {Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity},
  journal = {Angiogenesis},
  year = {2024},
  doi = {10.1007/s10456-024-09948-2}
}
Kostenlos starten →